Key result
Both CK-3579 and sematilide provided significant protection against sudden death due to ventricular fibrillation (80% and 70% survival, respectively, vs 20% in controls) in a canine model.
Why the study?
Do CK-3579 and sematilide prevent ventricular fibrillation and sudden death in a canine model of sudden coronary death?
Do CK-3579 and sematilide prevent ventricular fibrillation and sudden death in a canine model of sudden coronary death?
Absolute Event Rate: 80% vs 20%
Both CK-3579 and sematilide demonstrated class III antiarrhythmic properties and protected against ventricular fibrillation and sudden death in a canine post-MI ischemia model.
No takes yet. Share an insight, caveat, or question.
May inform class III development; leaves open translation from canine post-MI models.
Chi et al. (1990) studied Post-myocardial infarction with inducible ventricular tachycardia (n=30). CK-3579 and sematilide vs. Vehicle-treated control was evaluated on Survival against the development of sudden death due to ventricular fibrillation after induction of an acute ischemic event. Both CK-3579 and sematilide provided significant protection against sudden death due to ventricular fibrillation (80% and 70% survival, respectively, vs 20% in controls) in a canine model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: